Pressure Is On Cannabinoid Drug Developer GW As Sativex Fails First Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
GW Pharmaceuticals – a leader in development of cannabis plant-derived drugs – suffers setback with failure in its first Phase III study in cancer pain; results of two more studies are yet to be reported.
You may also be interested in...
Cannabis-Based Sativex Boosts Profits At GW Pharma
U.K. approval for Sativex breaks new regulatory ground, says company, clearing path for pipeline candidates.
GW Pharmaceuticals PLC
GW is developing cannabis-based pharmaceuticals using extracts taken from plants which are specially bred to optimize the therapeutic benefit of cannabis.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.